Osmind Raises $40 Million For Breakthrough Mental Health Research & Treatment

Osmind, a public benefit corporation helping clinical professionals and researchers advance new life-saving mental health treatments, announced a $40 million Series B investment led by DFJ Growth. The Series B round brings the total amount of funding for Osmind to $57 million since the company’s founding in 2020. Justin Kao, partner at DFJ Growth, and the co-founder of Helix, will join the Osmind Board of Directors.

Osmind helps the medical community administer, track, and study the efficacy of interventions such as ketamine, SPRAVATO®, and transcranial magnetic stimulation as treatments for the 14 million U.S. patients living . . .